Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis
Journal of Digestive Diseases,  Evidence Based Medicine  Clinical Article

Tong JL et al. – Once–daily (OD) mesalamine is as effective and has a comparable safety profile as multiple–daily (MD) regimens for the maintenance treatment of ulcerative colitis (UC), and is even more effective for inducing remission in active UC.

  • Electronic databases up to July 2011 were searched for related studies evaluating the efficacy of OD vs MD for treatment of UC.
  • Only randomized controlled trials (RCTs) were considered eligible.
  • Remission rates or relapse rates were analyzed using intention-to-treat (ITT) and per-protocol (PP) analysis.
  • Pooled relative risk (RR) and 95% confidence interval (CI) were calculated.
  • Publication bias was assessed with a funnel plot.

  • Overall 10 RCTs including 9 full-text manuscripts and one abstract met the inclusion criteria.
  • OD dosing of mesalamine was shown to be as effective as MD dosing for the maintenance of clinical remission in patients with quiescent UC (RR = 1.00, 95% CI 0.89–1.12) by ITT analysis.
  • For active UC, a mild but significant benefit was achieved by OD dosing compared with MD dosing (RR = 0.80, 95% CI 0.64–0.99).
  • Total adverse events were similar using OD and MD mesalamine in quiescent UC (RR = 1.06, 95% CI 0.93–1.20).
  • Compliance with OD was slightly better than with MD (RR = 0.92, 95% CI 0.82–1.03).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Gastroenterology Articles

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More